U.S. Industrial REITs Stock News

NasdaqGS:TBBK
NasdaqGS:TBBKBanks

Fed Rate Cut Doubts Put These US Bank Stocks In Focus

With Goldman Sachs arguing that markets may be misreading the Federal Reserve’s next move, short duration fixed income and cash style products are suddenly in the spotlight again. Cooling inflation, softer retail sales, and weaker employment data have pushed rate expectations into question, creating room for both opportunity and disappointment. This article reviews three US listed financial stocks that are exposed to this news backdrop and explains why they may warrant a closer look at this...
NYSE:TOST
NYSE:TOSTDiversified Financial

Does Toast’s Adyen Payments Expansion And Buybacks Change The Bull Case For Toast (TOST)?

In August 2026, Toast, Inc. reported higher second-quarter revenue of US$1,908 million and net income of US$154 million, alongside updates on its completed US$648.33 million share repurchase program and multiple new partnerships with Adyen, Google, and BWH Hotels. Together, these developments highlight Toast’s growing role as a payments and AI-enabled restaurant technology platform, extending beyond traditional point-of-sale tools into broader financial and hospitality ecosystems. We’ll now...
NasdaqCM:CORT
NasdaqCM:CORTPharmaceuticals

Corcept Therapeutics (CORT) Stock Looks Discounted On Sales But Premium Priced On Broader Checks

Corcept Therapeutics stock has delivered a 447.7% return over the past 5 years, yet broader valuation checks suggest the shares are not a straightforward bargain at current levels. That 447.7% five year gain puts Corcept Therapeutics in the category of stocks where past returns are high enough that pricing mistakes can matter more for new investors. Expectations around the durability of Corcept Therapeutics' revenue and cash flow, alongside any shift in how investors view its clinical and...
NYSE:HUM
NYSE:HUMHealthcare

Humana (HUM) Stock May Be Below Fair Value After Home Care Push

Humana stock has climbed 47.1% year to date, yet the valuation checks present a more mixed picture that asks investors to weigh the recent share price strength against what the fundamentals currently support. The 47.1% year to date return suggests expectations around Humana have reset higher and leaves less room for disappointment if sentiment cools. Recent moves to reshape Medicare Advantage exposure and expand Medicaid and home care capabilities can support earnings quality over time,...
NasdaqGS:DSP
NasdaqGS:DSPSoftware

Sprout Social Stock And 2 Digital Advertising Plays Riding The AI Video Spend Shift

AI video start up Higgsfield just pulled in $400mn at a $5.4b valuation, with annualised revenue moving from $20mn to $700mn in roughly a year, and a bigger share now coming from corporate subscriptions. That level of funding and enterprise interest can influence how brands allocate their marketing budgets. This article looks at 3 stocks that could be positioned to benefit from that shift and outlines key points to consider when deciding whether they deserve a place on your watchlist. The...
NasdaqGS:INDB
NasdaqGS:INDBBanks

What’s Going On With Independent Bank (INDB)?

Independent Bank (INDB) stock has been drawing investor interest after recent trading performance, with the share price last closing at $85.94. That result has put more focus on how the bank’s fundamentals stack up today. See our latest analysis for Independent Bank. Recent trading has added to a steady positive trend for Independent Bank, with a 90 day share price return of 10.92% and a 1 year total shareholder return of 32.75%. This points to momentum that reflects shifting expectations on...
NYSE:IMAX
NYSE:IMAXEntertainment

Record-Breaking China IMAX Box Office For Nolan’s The Odyssey Could Be A Game Changer For IMAX (IMAX)

IMAX China Holding, Inc. and IMAX Corporation recently reported that Christopher Nolan’s The Odyssey delivered a record-breaking August box office in China, with IMAX screens contributing 45% of the film’s nationwide receipts while representing less than 1% of total screens. The film’s exclusive use of IMAX’s next-generation film camera and sound technology highlights how proprietary formats can magnify audience demand and reinforce IMAX’s premium positioning with both filmmakers and...
NYSE:COUR
NYSE:COURConsumer Services

Is Coursera (COUR) Undervalued After Strong Sales Growth And EPS Gains?

Coursera (COUR) is back in focus after recent comments on its 15.1% annual sales growth and 68% annual earnings per share gain, along with expectations for additional sales expansion over the next year. See our latest analysis for Coursera. Despite Coursera’s recent sales and earnings updates, the 1 year total shareholder return is down 51.51% and the 3 year total shareholder return is down 64.32%. However, the 3 month share price return has risen 7.04% from a base of US$5.78, which points to...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Johnson & Johnson (JNJ) Stock Could Trade Below Fair Value While Earnings Look Rich

Johnson & Johnson stock has delivered a strong 69.8% return over the past three years, yet the current checks send mixed signals, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while traditional market multiples lean the other way. Over the past three years, Johnson & Johnson has returned 69.8% to shareholders, which puts more focus on whether the current price still leaves room for attractive long term returns. Progress in areas such as the seltorexant program...
NasdaqCM:SEZL
NasdaqCM:SEZLDiversified Financial

Sezzle (SEZL) Stock Looks Fairly Valued With Strong Returns But Richer Earnings

Sezzle stock has delivered a very large 3 year gain while the broader valuation checks suggest the shares no longer look like a clear bargain at the current price. After such a strong run, the key issue for investors is whether the recent re rating fairly reflects the company’s updated business model and risk profile. Over the last 3 years Sezzle has returned roughly 8.5x, which puts extra focus on whether today’s price still leaves room for a reasonable margin of safety. The planned shift...
NasdaqGS:COGT
NasdaqGS:COGTBiotechs

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Cogent Biosciences (COGT) recently reported second quarter 2026 results, with a net loss of US$96.41 million compared with US$73.53 million a year earlier. For the first half, net loss reached US$193.76 million versus US$145.52 million. See our latest analysis for Cogent Biosciences. The earnings update arrives after a very strong 1 year total shareholder return of 213.21%. The 90 day share price return of 21.38% and more recent 7 day share price decline of 8.67% suggest some momentum has...
NYSE:TPL
NYSE:TPLOil and Gas

How Investors May Respond To Texas Pacific Land (TPL) Strong Q2 Earnings And Shifting Revenue Mix

In the second quarter of 2026, Texas Pacific Land Corporation reported revenue of US$246.06 million and net income of US$153.93 million, with basic and diluted earnings per share from continuing operations of US$2.23, all higher than the same period in 2025. For the first half of 2026, the company’s revenue rose to US$482.88 million and net income to US$296.83 million, highlighting sustained earnings expansion that may influence how investors assess the balance between its oil royalty...